Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Reply to Yew et al., "Vitamin C and Mycobacterium tuberculosis Persisters".

Vilchèze C, Jacobs WR Jr.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01709-18. doi: 10.1128/AAC.01709-18. Print 2018 Nov. No abstract available.

PMID:
30355748
2.

Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis.

Tiwari S, van Tonder AJ, Vilchèze C, Mendes V, Thomas SE, Malek A, Chen B, Chen M, Kim J, Blundell TL, Parkhill J, Weinrick B, Berney M, Jacobs WR Jr.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):9779-9784. doi: 10.1073/pnas.1808874115. Epub 2018 Aug 24.

PMID:
30143580
3.

Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy.

Vilchèze C, Copeland J, Keiser TL, Weisbrod T, Washington J, Jain P, Malek A, Weinrick B, Jacobs WR Jr.

MBio. 2018 May 29;9(3). pii: e00938-18. doi: 10.1128/mBio.00938-18.

4.

Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity.

Harbut MB, Yang B, Liu R, Yano T, Vilchèze C, Cheng B, Lockner J, Guo H, Yu C, Franzblau SG, Petrassi HM, Jacobs WR Jr, Rubin H, Chatterjee AK, Wang F.

Angew Chem Int Ed Engl. 2018 Mar 19;57(13):3478-3482. doi: 10.1002/anie.201800260. Epub 2018 Feb 22.

5.

Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence.

Vilchèze C, Weinrick B, Leung LW, Jacobs WR Jr.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1599-1604. doi: 10.1073/pnas.1721545115. Epub 2018 Jan 30.

6.

Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice.

Vilchèze C, Kim J, Jacobs WR Jr.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02165-17. doi: 10.1128/AAC.02165-17. Print 2018 Mar.

7.

Addressing the Metabolic Stability of Antituberculars through Machine Learning.

Stratton TP, Perryman AL, Vilchèze C, Russo R, Li SG, Patel JS, Singleton E, Ekins S, Connell N, Jacobs WR Jr, Freundlich JS.

ACS Med Chem Lett. 2017 Sep 14;8(10):1099-1104. doi: 10.1021/acsmedchemlett.7b00299. eCollection 2017 Oct 12.

8.

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes.

Liu R, Lyu X, Batt SM, Hsu MH, Harbut MB, Vilchèze C, Cheng B, Ajayi K, Yang B, Yang Y, Guo H, Lin C, Gan F, Wang C, Franzblau SG, Jacobs WR Jr, Besra GS, Johnson EF, Petrassi M, Chatterjee AK, Fütterer K, Wang F.

Angew Chem Int Ed Engl. 2017 Oct 9;56(42):13011-13015. doi: 10.1002/anie.201707324. Epub 2017 Sep 7.

9.

Mycobacterium tuberculosis universal stress protein Rv2623 interacts with the putative ATP binding cassette (ABC) transporter Rv1747 to regulate mycobacterial growth.

Glass LN, Swapna G, Chavadi SS, Tufariello JM, Mi K, Drumm JE, Lam TT, Zhu G, Zhan C, Vilchéze C, Arcos J, Chen Y, Bi L, Mehta S, Porcelli SA, Almo SC, Yeh SR, Jacobs WR Jr, Torrelles JB, Chan J.

PLoS Pathog. 2017 Jul 28;13(7):e1006515. doi: 10.1371/journal.ppat.1006515. eCollection 2017 Jul.

10.

Defining a temporal order of genetic requirements for development of mycobacterial biofilms.

Yang Y, Thomas J, Li Y, Vilchèze C, Derbyshire KM, Jacobs WR Jr, Ojha AK.

Mol Microbiol. 2017 Sep;105(5):794-809. doi: 10.1111/mmi.13734. Epub 2017 Jul 7.

11.

Enhanced respiration prevents drug tolerance and drug resistance in Mycobacterium tuberculosis.

Vilchèze C, Hartman T, Weinrick B, Jain P, Weisbrod TR, Leung LW, Freundlich JS, Jacobs WR Jr.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4495-4500. doi: 10.1073/pnas.1704376114. Epub 2017 Apr 10.

12.

Acid-Fast Positive and Acid-Fast Negative Mycobacterium tuberculosis: The Koch Paradox.

Vilchèze C, Kremer L.

Microbiol Spectr. 2017 Mar;5(2). doi: 10.1128/microbiolspec.TBTB2-0003-2015. Review.

PMID:
28337966
13.

Dual-Reporter Mycobacteriophages (Φ2DRMs) Reveal Preexisting Mycobacterium tuberculosis Persistent Cells in Human Sputum.

Jain P, Weinrick BC, Kalivoda EJ, Yang H, Munsamy V, Vilcheze C, Weisbrod TR, Larsen MH, O'Donnell MR, Pym A, Jacobs WR Jr.

MBio. 2016 Oct 25;7(5). pii: e01023-16. doi: 10.1128/mBio.01023-16.

14.

Deletion of a dehydratase important for intracellular growth and cording renders rough Mycobacterium abscessus avirulent.

Halloum I, Carrère-Kremer S, Blaise M, Viljoen A, Bernut A, Le Moigne V, Vilchèze C, Guérardel Y, Lutfalla G, Herrmann JL, Jacobs WR Jr, Kremer L.

Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4228-37. doi: 10.1073/pnas.1605477113. Epub 2016 Jul 6.

15.

Targeting Mycobacterium tuberculosis Tumor Necrosis Factor Alpha-Downregulating Genes for the Development of Antituberculous Vaccines.

Olsen A, Chen Y, Ji Q, Zhu G, De Silva AD, Vilchèze C, Weisbrod T, Li W, Xu J, Larsen M, Zhang J, Porcelli SA, Jacobs WR Jr, Chan J.

MBio. 2016 May 31;7(3). pii: e01023-15. doi: 10.1128/mBio.01023-15.

16.

Separable roles for Mycobacterium tuberculosis ESX-3 effectors in iron acquisition and virulence.

Tufariello JM, Chapman JR, Kerantzas CA, Wong KW, Vilchèze C, Jones CM, Cole LE, Tinaztepe E, Thompson V, Fenyö D, Niederweis M, Ueberheide B, Philips JA, Jacobs WR Jr.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E348-57. doi: 10.1073/pnas.1523321113. Epub 2016 Jan 4.

17.

The Complete Genome Sequence of the Emerging Pathogen Mycobacterium haemophilum Explains Its Unique Culture Requirements.

Tufariello JM, Kerantzas CA, Vilchèze C, Calder RB, Nordberg EK, Fischer JA, Hartman TE, Yang E, Driscoll T, Cole LE, Sebra R, Maqbool SB, Wattam AR, Jacobs WR Jr.

MBio. 2015 Nov 17;6(6):e01313-15. doi: 10.1128/mBio.01313-15.

18.

Evolution of a thienopyrimidine antitubercular relying on medicinal chemistry and metabolomics insights.

Li SG, Vilchèze C, Chakraborty S, Wang X, Kim H, Anisetti M, Ekins S, Rhee KY, Jacobs WR Jr, Freundlich JS.

Tetrahedron Lett. 2015 Jun 3;56(23):3246-3250.

19.

Synthesis and biological activity of alkynoic acids derivatives against mycobacteria.

Vilchèze C, Leung LW, Bittman R, Jacobs WR Jr.

Chem Phys Lipids. 2016 Jan;194:125-38. doi: 10.1016/j.chemphyslip.2015.08.001. Epub 2015 Aug 6.

20.

Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities.

Vilchèze C, Jacobs WR Jr.

Microbiol Spectr. 2014 Aug;2(4):MGM2-0014-2013. doi: 10.1128/microbiolspec.MGM2-0014-2013. Review.

PMID:
26104204
21.

Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.

Harbut MB, Vilchèze C, Luo X, Hensler ME, Guo H, Yang B, Chatterjee AK, Nizet V, Jacobs WR Jr, Schultz PG, Wang F.

Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4453-8. doi: 10.1073/pnas.1504022112. Epub 2015 Mar 23.

22.

Succinate dehydrogenase is the regulator of respiration in Mycobacterium tuberculosis.

Hartman T, Weinrick B, Vilchèze C, Berney M, Tufariello J, Cook GM, Jacobs WR Jr.

PLoS Pathog. 2014 Nov 20;10(11):e1004510. doi: 10.1371/journal.ppat.1004510. eCollection 2014 Nov.

23.

Energetics of Respiration and Oxidative Phosphorylation in Mycobacteria.

Cook GM, Hards K, Vilchèze C, Hartman T, Berney M.

Microbiol Spectr. 2014 Jun;2(3). doi: 10.1128/microbiolspec.MGM2-0015-2013. Review.

24.

Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.

Stec J, Vilchèze C, Lun S, Perryman AL, Wang X, Freundlich JS, Bishai W, Jacobs WR Jr, Kozikowski AP.

ChemMedChem. 2014 Nov;9(11):2528-37. doi: 10.1002/cmdc.201402255. Epub 2014 Aug 27.

25.

Enhanced specialized transduction using recombineering in Mycobacterium tuberculosis.

Tufariello JM, Malek AA, Vilchèze C, Cole LE, Ratner HK, González PA, Jain P, Hatfull GF, Larsen MH, Jacobs WR Jr.

MBio. 2014 May 27;5(3):e01179-14. doi: 10.1128/mBio.01179-14.

26.

Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis.

Vilchèze C, Molle V, Carrère-Kremer S, Leiba J, Mourey L, Shenai S, Baronian G, Tufariello J, Hartman T, Veyron-Churlet R, Trivelli X, Tiwari S, Weinrick B, Alland D, Guérardel Y, Jacobs WR Jr, Kremer L.

PLoS Pathog. 2014 May 8;10(5):e1004115. doi: 10.1371/journal.ppat.1004115. eCollection 2014 May.

27.

Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent--authors' response.

Ramón-García S, Vilchèze C, Lim LE, Ng C, Jacobs WR Jr, Thompson CJ.

J Antimicrob Chemother. 2014 Jun;69(6):1725-6. doi: 10.1093/jac/dku117. Epub 2014 Apr 9. No abstract available.

PMID:
24722835
28.

Acetic Acid, the active component of vinegar, is an effective tuberculocidal disinfectant.

Cortesia C, Vilchèze C, Bernut A, Contreras W, Gómez K, de Waard J, Jacobs WR Jr, Kremer L, Takiff H.

MBio. 2014 Feb 25;5(2):e00013-14. doi: 10.1128/mBio.00013-14.

29.

Measurements of the in vitro anti-mycobacterial activity of ivermectin are method-dependent.

Ramón-García S, Vilchèze C, Lim LE, Ng C, Jacobs WR Jr, Thompson CJ.

J Antimicrob Chemother. 2014 Jun;69(6):1723-4. doi: 10.1093/jac/dku037. Epub 2014 Feb 25. No abstract available.

PMID:
24569629
30.

Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis.

Wilson R, Kumar P, Parashar V, Vilchèze C, Veyron-Churlet R, Freundlich JS, Barnes SW, Walker JR, Szymonifka MJ, Marchiano E, Shenai S, Colangeli R, Jacobs WR Jr, Neiditch MB, Kremer L, Alland D.

Nat Chem Biol. 2013 Aug;9(8):499-506. doi: 10.1038/nchembio.1277. Epub 2013 Jun 16.

31.

Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction.

Vilchèze C, Hartman T, Weinrick B, Jacobs WR Jr.

Nat Commun. 2013;4:1881. doi: 10.1038/ncomms2898.

32.

Keto-mycolic acid-dependent pellicle formation confers tolerance to drug-sensitive Mycobacterium tuberculosis.

Sambandan D, Dao DN, Weinrick BC, Vilchèze C, Gurcha SS, Ojha A, Kremer L, Besra GS, Hatfull GF, Jacobs WR Jr.

MBio. 2013 May 7;4(3):e00222-13. doi: 10.1128/mBio.00222-13.

33.

Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains.

Lim LE, Vilchèze C, Ng C, Jacobs WR Jr, Ramón-García S, Thompson CJ.

Antimicrob Agents Chemother. 2013 Feb;57(2):1040-6. doi: 10.1128/AAC.01696-12. Epub 2012 Nov 19.

34.

The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis.

Vilchèze C, Jacobs WR Jr.

Antimicrob Agents Chemother. 2012 Oct;56(10):5142-8. doi: 10.1128/AAC.00832-12. Epub 2012 Jul 23.

35.

Einstein Contained Aerosol Pulmonizer (ECAP): Improved Biosafety for Multi-Drug Resistant (MDR) and Extensively Drug Resistant (XDR) Mycobacterium tuberculosis Aerosol Infection Studies.

Chen B, Weisbrod TR, Hsu T, Sambandamurthy V, Vieira-Cruz D, Chibbaro A, Ghidoni D, Kile T, Barkley WE, Vilchèze C, Colon-Berezin C, Thaler DS, Larsen MH, Sturm AW, Jacobs WR Jr.

Appl Biosaf. 2011 Oct 27;16(3):134-138.

36.

Coresistance to isoniazid and ethionamide maps to mycothiol biosynthetic genes in Mycobacterium bovis.

Vilchèze C, Av-Gay Y, Barnes SW, Larsen MH, Walker JR, Glynne RJ, Jacobs WR Jr.

Antimicrob Agents Chemother. 2011 Sep;55(9):4422-3. doi: 10.1128/AAC.00564-11. Epub 2011 Jun 27.

37.

Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.

Vilchèze C, Baughn AD, Tufariello J, Leung LW, Kuo M, Basler CF, Alland D, Sacchettini JC, Freundlich JS, Jacobs WR Jr.

Antimicrob Agents Chemother. 2011 Aug;55(8):3889-98. doi: 10.1128/AAC.00266-11. Epub 2011 May 31.

38.

Precise null deletion mutations of the mycothiol synthesis genes reveal their role in isoniazid and ethionamide resistance in Mycobacterium smegmatis.

Xu X, Vilchèze C, Av-Gay Y, Gómez-Velasco A, Jacobs WR Jr.

Antimicrob Agents Chemother. 2011 Jul;55(7):3133-9. doi: 10.1128/AAC.00020-11. Epub 2011 Apr 18.

39.

Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of Mycobacterium tuberculosis.

Molle V, Gulten G, Vilchèze C, Veyron-Churlet R, Zanella-Cléon I, Sacchettini JC, Jacobs WR Jr, Kremer L.

Mol Microbiol. 2010 Dec;78(6):1591-605. doi: 10.1111/j.1365-2958.2010.07446.x. Epub 2010 Nov 9.

40.

Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy.

Baughn AD, Deng J, Vilchèze C, Riestra A, Welch JT, Jacobs WR Jr, Zimhony O.

Antimicrob Agents Chemother. 2010 Dec;54(12):5323-8. doi: 10.1128/AAC.00529-10. Epub 2010 Sep 27. Erratum in: Antimicrob Agents Chemother. 2011 Apr;55(4):1826.

41.

Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid.

Wang F, Jain P, Gulten G, Liu Z, Feng Y, Ganesula K, Motiwala AS, Ioerger TR, Alland D, Vilchèze C, Jacobs WR Jr, Sacchettini JC.

Antimicrob Agents Chemother. 2010 Sep;54(9):3776-82. doi: 10.1128/AAC.00453-10. Epub 2010 Jun 21.

42.

Trichoderins, novel aminolipopeptides from a marine sponge-derived Trichoderma sp., are active against dormant mycobacteria.

Pruksakorn P, Arai M, Kotoku N, Vilchèze C, Baughn AD, Moodley P, Jacobs WR Jr, Kobayashi M.

Bioorg Med Chem Lett. 2010 Jun 15;20(12):3658-63. doi: 10.1016/j.bmcl.2010.04.100. Epub 2010 Apr 26.

PMID:
20483615
43.

NAD+ auxotrophy is bacteriocidal for the tubercle bacilli.

Vilchèze C, Weinrick B, Wong KW, Chen B, Jacobs WR Jr.

Mol Microbiol. 2010 Apr;76(2):365-77. doi: 10.1111/j.1365-2958.2010.07099.x. Epub 2010 Feb 28.

44.

An anaerobic-type alpha-ketoglutarate ferredoxin oxidoreductase completes the oxidative tricarboxylic acid cycle of Mycobacterium tuberculosis.

Baughn AD, Garforth SJ, Vilchèze C, Jacobs WR Jr.

PLoS Pathog. 2009 Nov;5(11):e1000662. doi: 10.1371/journal.ppat.1000662. Epub 2009 Nov 20.

45.

Triclosan derivatives: towards potent inhibitors of drug-sensitive and drug-resistant Mycobacterium tuberculosis.

Freundlich JS, Wang F, Vilchèze C, Gulten G, Langley R, Schiehser GA, Jacobus DP, Jacobs WR Jr, Sacchettini JC.

ChemMedChem. 2009 Feb;4(2):241-8. doi: 10.1002/cmdc.200800261.

46.

The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites.

Yu M, Kumar TR, Nkrumah LJ, Coppi A, Retzlaff S, Li CD, Kelly BJ, Moura PA, Lakshmanan V, Freundlich JS, Valderramos JC, Vilcheze C, Siedner M, Tsai JH, Falkard B, Sidhu AB, Purcell LA, Gratraud P, Kremer L, Waters AP, Schiehser G, Jacobus DP, Janse CJ, Ager A, Jacobs WR Jr, Sacchettini JC, Heussler V, Sinnis P, Fidock DA.

Cell Host Microbe. 2008 Dec 11;4(6):567-78. doi: 10.1016/j.chom.2008.11.001.

47.

Isolation and analysis of Mycobacterium tuberculosis mycolic acids.

Vilchèze C, Jacobs WR.

Curr Protoc Microbiol. 2007 Jun;Chapter 10:Unit 10A.3. doi: 10.1002/9780471729259.mc10a03s05.

PMID:
18770604
48.

Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis.

Vilchèze C, Av-Gay Y, Attarian R, Liu Z, Hazbón MH, Colangeli R, Chen B, Liu W, Alland D, Sacchettini JC, Jacobs WR Jr.

Mol Microbiol. 2008 Sep;69(5):1316-29. doi: 10.1111/j.1365-2958.2008.06365.x. Epub 2008 Jul 21.

49.

Halicyclamine A, a marine spongean alkaloid as a lead for anti-tuberculosis agent.

Arai M, Sobou M, Vilchéze C, Baughn A, Hashizume H, Pruksakorn P, Ishida S, Matsumoto M, Jacobs WR Jr, Kobayashi M.

Bioorg Med Chem. 2008 Jul 15;16(14):6732-6. doi: 10.1016/j.bmc.2008.05.061. Epub 2008 Jun 13.

PMID:
18556206
50.

The mechanism of isoniazid killing: clarity through the scope of genetics.

Vilchèze C, Jacobs WR Jr.

Annu Rev Microbiol. 2007;61:35-50. Review.

PMID:
18035606

Supplemental Content

Loading ...
Support Center